MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- BIOCON - GLENMARK PHARMA
BIOCON vs GLENMARK PHARMA - Comparison Results
BIOCON Change
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
GLENMARK PHARMA 
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
Current Valuations
| BIOCON | GLENMARK PHARMA | BIOCON / GLENMARK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 31.6 | 15.1 | 209.9% | View Chart |
| P/BV | x | 3.8 | 2.5 | 152.3% | View Chart |
| Dividend Yield | % | 0.3 | 0.4 | 64.2% |
Financials
 BIOCON  GLENMARK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| BIOCON Mar-19 |
GLENMARK PHARMA Mar-19 |
BIOCON / GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 707 | 712 | 99.4% | |
| Low | Rs | 554 | 484 | 114.5% | |
| Sales per share (Unadj.) | Rs | 91.9 | 349.6 | 26.3% | |
| Earnings per share (Unadj.) | Rs | 16.7 | 32.8 | 51.0% | |
| Cash flow per share (Unadj.) | Rs | 24.2 | 44.3 | 54.5% | |
| Dividends per share (Unadj.) | Rs | 1.00 | 2.00 | 50.0% | |
| Dividend yield (eoy) | % | 0.2 | 0.3 | 47.4% | |
| Book value per share (Unadj.) | Rs | 101.6 | 198.6 | 51.2% | |
| Shares outstanding (eoy) | m | 600.00 | 282.17 | 212.6% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 6.9 | 1.7 | 401.4% | |
| Avg P/E ratio | x | 37.7 | 18.2 | 207.0% | |
| P/CF ratio (eoy) | x | 26.1 | 13.5 | 193.5% | |
| Price / Book Value ratio | x | 6.2 | 3.0 | 206.2% | |
| Dividend payout | % | 6.0 | 6.1 | 98.1% | |
| Avg Mkt Cap | Rs m | 378,330 | 168,625 | 224.4% | |
| No. of employees | `000 | 6.1 | 12.0 | 50.9% | |
| Total wages/salary | Rs m | 11,653 | 20,561 | 56.7% | |
| Avg. sales/employee | Rs Th | 8,994.3 | 8,196.0 | 109.7% | |
| Avg. wages/employee | Rs Th | 1,900.7 | 1,708.1 | 111.3% | |
| Avg. net profit/employee | Rs Th | 1,635.3 | 768.5 | 212.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 55,144 | 98,655 | 55.9% | |
| Other income | Rs m | 1,444 | 2,081 | 69.4% | |
| Total revenues | Rs m | 56,588 | 100,736 | 56.2% | |
| Gross profit | Rs m | 15,883 | 15,858 | 100.2% | |
| Depreciation | Rs m | 4,478 | 3,259 | 137.4% | |
| Interest | Rs m | 709 | 3,346 | 21.2% | |
| Profit before tax | Rs m | 12,140 | 11,335 | 107.1% | |
| Minority Interest | Rs m | 9 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
| Tax | Rs m | 2,123 | 3,756 | 56.5% | |
| Profit after tax | Rs m | 10,026 | 9,250 | 108.4% | |
| Gross profit margin | % | 28.8 | 16.1 | 179.2% | |
| Effective tax rate | % | 17.5 | 33.1 | 52.8% | |
| Net profit margin | % | 18.2 | 9.4 | 193.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 48,228 | 66,968 | 72.0% | |
| Current liabilities | Rs m | 30,376 | 40,211 | 75.5% | |
| Net working cap to sales | % | 32.4 | 27.1 | 119.4% | |
| Current ratio | x | 1.6 | 1.7 | 95.3% | |
| Inventory Days | Days | 68 | 83 | 82.0% | |
| Debtors Days | Days | 86 | 81 | 105.3% | |
| Net fixed assets | Rs m | 64,130 | 33,322 | 192.5% | |
| Share capital | Rs m | 3,000 | 282 | 1,063.1% | |
| "Free" reserves | Rs m | 57,980 | 55,770 | 104.0% | |
| Net worth | Rs m | 60,980 | 56,052 | 108.8% | |
| Long term debt | Rs m | 15,766 | 35,738 | 44.1% | |
| Total assets | Rs m | 121,924 | 132,888 | 91.7% | |
| Interest coverage | x | 18.1 | 4.4 | 413.0% | |
| Debt to equity ratio | x | 0.3 | 0.6 | 40.6% | |
| Sales to assets ratio | x | 0.5 | 0.7 | 60.9% | |
| Return on assets | % | 8.8 | 9.5 | 92.9% | |
| Return on equity | % | 16.4 | 16.5 | 99.6% | |
| Return on capital | % | 16.8 | 17.8 | 94.0% | |
| Exports to sales | % | 28.1 | 0 | - | |
| Imports to sales | % | 18.9 | 0 | - | |
| Exports (fob) | Rs m | 15,506 | NA | - | |
| Imports (cif) | Rs m | 10,399 | NA | - | |
| Fx inflow | Rs m | 15,506 | 62,998 | 24.6% | |
| Fx outflow | Rs m | 10,399 | 22,859 | 45.5% | |
| Net fx | Rs m | 5,107 | 40,140 | 12.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 11,546 | 13,242 | 87.2% | |
| From Investments | Rs m | -7,138 | -6,990 | 102.1% | |
| From Financial Activity | Rs m | -2,417 | -7,387 | 32.7% | |
| Net Cashflow | Rs m | 2,103 | -2,971 | -70.8% | |
Share Holding
| Indian Promoters | % | 40.4 | 48.3 | 83.6% | |
| Foreign collaborators | % | 20.6 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.4 | 6.9 | 121.7% | |
| FIIs | % | 10.7 | 34.4 | 31.1% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 19.9 | 10.5 | 189.5% | |
| Shareholders | 109,995 | 56,727 | 193.9% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: ALEMBIC PHARMA STRIDES PHARMA SCIENCE FULFORD INDIA ASTRAZENECA PHARMA DIVIS LABORATORIES
Compare BIOCON With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
Related Views on News
BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)
Jan 25, 2021 | Updated on Jan 25, 2021For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)
Oct 29, 2020 | Updated on Oct 29, 2020For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)
Sep 1, 2020 | Updated on Sep 1, 2020For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)
Feb 19, 2020 | Updated on Feb 19, 2020For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)
Jan 24, 2020 | Updated on Jan 24, 2020For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsMost Popular
Time to Book Profits in Pharma Stocks(Fast Profits Daily)
Jan 15, 2021In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)
Jan 15, 2021The pandemic failed to thwart Richa's investing success formula for 2020.
Buzzing Sectors Before Budget 2021(Fast Profits Daily)
Jan 12, 2021The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)
Jan 12, 2021Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
BIOCON SHARE PRICE
Jan 25, 2021 03:36 PM
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON - ORCHID PHARMA COMPARISON
COMPARE BIOCON WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.